OTC Ear Care Firm Eosera Gets Earful From US FDA On Pain And Itch Remedies, GMP Compliance
Executive Summary
Eosera has removed its Ear Pain MD and Ear Itch MD products from e-commerce pages on its website following FDA's warning letter. The warning identifying the pain and itch products as unapproved new drugs also states that a January inspection of the firm’s facility found GMP violations.
You may also be interested in...
US FDA Warns Foreign Manufacturers Of OTC Analgesics For Monograph Non-Compliance
Malaysia-based Furley Bioextracts and Honduras-based Laboratorio Pharma International receive warning letters from the US FDA following import alerts in May and June for marketing products as OTC analgesic drugs without complying with controlling monograph conditions.
Eosera Expands Into Nasal Care While Linking App For Live Video With Latest Ear Care Line Extension
Eosera is launching two devices for cleaning and taking pictures of ears, while also entering the nasal care segment with an irrigation product that uses gravity to flush saline through the nostrils.
OTC Topicals After Bite, Itch Eraser Are Irritants To US FDA Monograph, GMP Regulations
Adventure Ready Brands is the second small firm warned recently by FDA about manufacturing and marketing products labeled as nonprescription drugs but noncompliant with relevant OTC drug monographs and about GMP violations.